Drug name - Anjeso

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512727 BAUDAX Nanoparticulate meloxicam formulations Dec, 2022

(2 months from now)

US10463673 BAUDAX Nanoparticulate meloxicam formulations Feb, 2024

(1 year, 4 months from now)

US10471067 BAUDAX Nanoparticulate meloxicam formulations Feb, 2024

(1 year, 4 months from now)

US10709713 BAUDAX Nanoparticulate meloxicam formulations May, 2030

(7 years from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions May, 2030

(7 years from now)

US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions May, 2030

(7 years from now)

US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment Mar, 2039

(16 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30MG/ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.